| Autor: |
Carril-Ajuria L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Remolina-Bonilla YA; Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Carretero-Gonzalez A; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Martin-Soberon M; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Castellano D; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Bourlon C; Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico., de Velasco G; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Bourlon MT; Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico. |
| Abstrakt: |
A 78-year-old man had a medical history of hypertension, atrial fibrillation, chronic kidney disease, and metastatic castration-resistant prostate cancer (CRPC). He had progressed to first-line therapy for CRPC with abiraterone plus androgen-deprivation therapy (ADT) and as second-line therapy he was being treated with docetaxel, with biochemical progression in his last prostate specific antigen measurement. He was admitted to the hospital on April 2020, in the middle of the coronavirus disease 2019 (COVID-19) pandemic, because of painful bone lesions and deterioration of renal function. |
